Literature DB >> 30707045

The assistance of coblation in arytenoidectomy for vocal cord paralysis.

Yuqiang Hu1, Liangjun Cheng1, Bing Liu1, Hao Ming1, Aimin Tian1, Mei Ma1.   

Abstract

BACKGROUND: There are many causes for vocal cord paralysis, which can cause difficulty in breathing in serious cases. The common surgical methods for solving vocal cord paralysis include laryngeal splitting or laser surgery, but there are limitations. Plasma radiofrequency ablation is a new treatment with good achievements in clinical applications.
OBJECTIVE: To investigate the effect of coblation-assisted arytenoidectomy (CSA) in the treatment of bilateral vocal cord paralysis (BVCP).
METHODS: All patients had undergone preoperative electrolaryngoscopic examination of the glottidis rima; electronic laryngoscopy can assess the width of the glottis. The purpose of preoperative electronic laryngoscopic evaluation is to assess the width of the glottis, and arytenoid cartilage movement. Unilateral arytenoid cartilage and a section of the vocal cords were removed in all cases.
RESULTS: Of the 14 patients, 13 were successfully extubated after CSA; 1 patient could not be extubated and underwent a second CSA of the contralateral arytenoid cartilage, after which extubation was achieved. All patients were continuously followed up (6 months to 2 years), and all achieved satisfactory results. CONCLUSIONS AND SIGNIFICANCE: CSA can effectively relieve post-CSA dyspnea in patients with BVCP. More patients underwent tracheal cannula extubation after tracheotomy compared with other surgeries.

Entities:  

Keywords:  Vocal cord paralysis; coblation; laryngoscopy

Mesh:

Year:  2019        PMID: 30707045     DOI: 10.1080/00016489.2018.1542160

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  1 in total

1.  Endoscopic coblation-assisted and partial arytenoidectomy for infants with idiopathic bilateral vocal cord paralysis.

Authors:  Letian Tan; Chao Chen; Qi Li
Journal:  Medicine (Baltimore)       Date:  2022-01-28       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.